Drotrecogin alpha (activated) in neonatal septic shock

A 12-d-old neonate suffering from group B streptococcal septic shock was treated with 24 μg/kg/h recombinant human activated protein C [rhAPC, drotrecogin alpha (activated)] for 96 h. The protein C activity increased from 5% to 53% after rhAPC infusion. The patient recovered within 14 d without any...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of infectious diseases 2005-04, Vol.37 (4), p.306-308
Main Authors: Frommhold, David, Birle, Alexandra, Linderkamp, Otwin, Zilow, Eugen P., Pöschl, Johannes M.B.
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Anti-Infective Agents - therapeutic use
Biological and medical sciences
Emergency and intensive care: infection, septic shock
Humans
Infant, Newborn
Intensive care medicine
Male
Medical sciences
Meningitis, Pneumococcal - complications
Protein C - therapeutic use
Recombinant Proteins - therapeutic use
Shock, Septic - drug therapy
Streptococcal Infections - drug therapy
Streptococcus agalactiae
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 12-d-old neonate suffering from group B streptococcal septic shock was treated with 24 μg/kg/h recombinant human activated protein C [rhAPC, drotrecogin alpha (activated)] for 96 h. The protein C activity increased from 5% to 53% after rhAPC infusion. The patient recovered within 14 d without any adverse effects.
ISSN:0036-5548
1651-1980
DOI:10.1080/00365540510031412